We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?
Read MoreHide Full Article
Key Takeaways
MED's 3.0 strategy shifts its focus from weight loss toward a comprehensive metabolic health system.
The Catalyst program targets facility rationalization, AI efficiencies and other cost savings in 2026.
MED aims to return to profitability by the fourth quarter of 2026 while pursuing revenue growth.
Medifast, Inc.’s (MED - Free Report) 3.0 strategy represents its most significant strategic shift since the launch of OPTAVIA in 2017, moving the company beyond its traditional weight-loss positioning toward a comprehensive metabolic health system under its new consumer brand, Trilivy. The strategy is built around a 10-year roadmap aimed at expanding the company’s offering to coaches and clients within a comprehensive metabolic health system. At the same time, Medifast plans to broaden its geographic and demographic footprints, positioning 3.0 as a long-term strategic shift for the company.
Medifast’s 3.0 organization is centered on four core characteristics: speed, simplicity, scale, and stewardship. The company is emphasizing the need to move quickly to capture the opportunity in metabolic health while simultaneously working to return the business to profitability. This focus on speed is reflected in the launch of a series of new initiatives, alongside an emphasis on maintaining a sustainable pace of execution. Management is also looking for ways to do more with less as it executes the 3.0 strategy.
To accelerate its path back to profitability, the company launched its Catalyst program, with the majority of execution expected in the third quarter of 2026, to drive additional cost savings across the business. The program focuses on facility rationalization, AI-related efficiencies, and other cost-saving measures while ensuring that the company’s ability to grow is not negatively impacted.
Management is simultaneously working to improve profitability by pursuing revenue growth initiatives and eliminating costs across the business. The near-term objective is to return to profitability by the fourth quarter of 2026, with management believing it remains on track to achieve this goal. Overall, Medifast’s renewed strategic direction is intended to broaden its opportunity in metabolic health, while improving cost efficiency and positioning the business for a return to profitability.
The Zacks Rundown for MED
The Zacks Rank #2 (Buy) company's shares have gained 17.5% in the past six months against the industry’s decline of 1.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.50, lower than the industry’s average of 0.82.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 26.8%, whereas the same for next fiscal year earnings suggests 54.8% growth year over year.
Image Source: Zacks Investment Research
Other Stocks to Consider
Some other top-ranked stocks have been discussed below:
The Chef’s Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East, and Canada. CHEF currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CHEF’s current fiscal-year sales and earnings indicates growth of 10.6% and 33.7%, respectively, from the year-ago reported figures. CHEF delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Darling Ingredients Inc. (DAR - Free Report) develops, produces, and sells sustainable natural ingredients from edible and inedible bio-nutrients in North America, Europe, China, South America, and internationally. DAR currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for DAR’s current fiscal-year sales and earnings implies growth of 11.5% and 926.5%, respectively, from the year-ago actuals. DAR delivered a trailing four-quarter negative earnings surprise of 38.9%, on average.
Utz Brands, Inc. (UTZ - Free Report) , together with its subsidiaries, markets, sells and distributes fresh, frozen, and dry food and non-food products to foodservice customers in the United States. UTZ currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for UTZ’s current fiscal-year sales implies growth of 3.7%, and the same for earnings implies a decline of 2.4%, from the year-ago actuals. UTZ delivered a trailing four-quarter earnings surprise of 1.8%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?
Key Takeaways
Medifast, Inc.’s (MED - Free Report) 3.0 strategy represents its most significant strategic shift since the launch of OPTAVIA in 2017, moving the company beyond its traditional weight-loss positioning toward a comprehensive metabolic health system under its new consumer brand, Trilivy. The strategy is built around a 10-year roadmap aimed at expanding the company’s offering to coaches and clients within a comprehensive metabolic health system. At the same time, Medifast plans to broaden its geographic and demographic footprints, positioning 3.0 as a long-term strategic shift for the company.
Medifast’s 3.0 organization is centered on four core characteristics: speed, simplicity, scale, and stewardship. The company is emphasizing the need to move quickly to capture the opportunity in metabolic health while simultaneously working to return the business to profitability. This focus on speed is reflected in the launch of a series of new initiatives, alongside an emphasis on maintaining a sustainable pace of execution. Management is also looking for ways to do more with less as it executes the 3.0 strategy.
To accelerate its path back to profitability, the company launched its Catalyst program, with the majority of execution expected in the third quarter of 2026, to drive additional cost savings across the business. The program focuses on facility rationalization, AI-related efficiencies, and other cost-saving measures while ensuring that the company’s ability to grow is not negatively impacted.
Management is simultaneously working to improve profitability by pursuing revenue growth initiatives and eliminating costs across the business. The near-term objective is to return to profitability by the fourth quarter of 2026, with management believing it remains on track to achieve this goal. Overall, Medifast’s renewed strategic direction is intended to broaden its opportunity in metabolic health, while improving cost efficiency and positioning the business for a return to profitability.
The Zacks Rundown for MED
The Zacks Rank #2 (Buy) company's shares have gained 17.5% in the past six months against the industry’s decline of 1.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.50, lower than the industry’s average of 0.82.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 26.8%, whereas the same for next fiscal year earnings suggests 54.8% growth year over year.
Image Source: Zacks Investment Research
Other Stocks to Consider
Some other top-ranked stocks have been discussed below:
The Chef’s Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East, and Canada. CHEF currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CHEF’s current fiscal-year sales and earnings indicates growth of 10.6% and 33.7%, respectively, from the year-ago reported figures. CHEF delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Darling Ingredients Inc. (DAR - Free Report) develops, produces, and sells sustainable natural ingredients from edible and inedible bio-nutrients in North America, Europe, China, South America, and internationally. DAR currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for DAR’s current fiscal-year sales and earnings implies growth of 11.5% and 926.5%, respectively, from the year-ago actuals. DAR delivered a trailing four-quarter negative earnings surprise of 38.9%, on average.
Utz Brands, Inc. (UTZ - Free Report) , together with its subsidiaries, markets, sells and distributes fresh, frozen, and dry food and non-food products to foodservice customers in the United States. UTZ currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for UTZ’s current fiscal-year sales implies growth of 3.7%, and the same for earnings implies a decline of 2.4%, from the year-ago actuals. UTZ delivered a trailing four-quarter earnings surprise of 1.8%, on average.